EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Molecular biology of cholangiocarcinoma and its implications for targeted therapy in patient management

T M Gilbert, L Randle, M Quinn, O McGreevy, L O'leary, R Young, R Diaz-Neito, R P Jones, B Greenhalf, C Goldring, S Fenwick, H Malik und 1 weitere

European Journal of Surgical Oncology · 2025

DOI: 10.1016/j.ejso.2024.108352 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Surgical Oncology, 2025. Verfasst von T M Gilbert und 12 weiteren Autor:innen. Beteiligte Einrichtung: Hepatobiliary Surgery, Liverpool University Hospitals NHS FT, Liverpool, UK; Department of Pharmacology and Therapeutics, Institute of Systems Integr…. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms, Molecular Targeted Therapy, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 94 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cholangiocarcinoma (CCA) remains a devastating malignancy and a significant challenge to treat. The majority of CCA patients are diagnosed at an advanced stage, making the disease incurable in most cases. The advent of high-throughput genetic sequencing has significantly improved our understanding of the molecular biology underpinning cancer. The identification of 'druggable' genetic aberrations and the development of novel targeted therapies against them is opening up new treatment strategies. Currently, 3 targeted therapies are approved for use in CCA; Ivosidenib in patients with IDH1 mutations and Infigratinib/Pemigatinib in those with FGFR2 fusions. As our understanding of the biology underpinning CCA continues to improve it is highly likely that additional targeted therapies will become available in the near future. This is important, as it is thought up to 40 % of CCA patients harbour a potentially actionable mutation. In this review we provide an overview of the molecular pathogenesis of CCA and highlight currently available and potential future targeted treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaBile Duct NeoplasmsMolecular Targeted TherapyAntineoplastic AgentsHumansMutationIsocitrate DehydrogenaseReceptor, Fibroblast Growth Factor, Type 2PyridinesGlycinePyrimidinesPyrrolesPyridazinesMorpholinesPhenylurea Compounds

Stichwörter der Autor:innen

CholangiocarcinomaMolecular biologyPatient treatmentTargeted therapy

Substanzen

Isocitrate DehydrogenaseReceptor, Fibroblast Growth Factor, Type 2PyridinesAntineoplastic AgentsFGFR2 protein, humanGlycineIDH1 protein, humanpemigatinibPyrimidinesivosidenib

Autor:innen und Institutionen

  • Hepatobiliary Surgery, Liverpool University Hospitals NHS FT, Liverpool, UK; Department of Pharmacology and Therapeutics, Institute of Systems Integrative and Molecular Biology, University of Liverpool, Liverpool, UK. E…
  • Department of Pharmacology and Therapeutics, Institute of Systems Integrative and Molecular Biology, University of Liverpool, Liverpool, UK.
  • Hepatobiliary Surgery, Liverpool University Hospitals NHS FT, Liverpool, UK.
  • Hepatobiliary Surgery, Liverpool University Hospitals NHS FT, Liverpool, UK; Department of Pharmacology and Therapeutics, Institute of Systems Integrative and Molecular Biology, University of Liverpool, Liverpool, UK.
  • Liverpool Experimental Cancer Medicines Centre, University of Liverpool, Liverpool, UK.
  • Clatterbridge Cancer Centre, Liverpool, UK; Liverpool Experimental Cancer Medicines Centre, University of Liverpool, Liverpool, UK.

Zitieren

APA

Gilbert, T. M., Randle, L., Quinn, M., McGreevy, O., O'leary, L., Young, R., Diaz-Neito, R., Jones, R. P., Greenhalf, B., Goldring, C., Fenwick, S., Malik, H., & Palmer, D. H. (2025). Molecular biology of cholangiocarcinoma and its implications for targeted therapy in patient management. European Journal of Surgical Oncology. https://doi.org/10.1016/j.ejso.2024.108352

Vancouver

Gilbert TM, Randle L, Quinn M, McGreevy O, O'leary L, Young R, et al. Molecular biology of cholangiocarcinoma and its implications for targeted therapy in patient management. European Journal of Surgical Oncology. 2025. doi:10.1016/j.ejso.2024.108352

BibTeX
@article{Gilbert2025,
  author = {Gilbert, T M and Randle, L and Quinn, M and McGreevy, O and O'leary, L and Young, R and Diaz-Neito, R and Jones, R P and Greenhalf, B and Goldring, C and Fenwick, S and Malik, H and Palmer, D H},
  title = {Molecular biology of cholangiocarcinoma and its implications for targeted therapy in patient management},
  journal = {European Journal of Surgical Oncology},
  year = {2025},
  doi = {10.1016/j.ejso.2024.108352}
}
Kostenlos starten →